Acutaas Q2 FY27 Revenue Surges 42.7% to ₹4,369 Million; Guides FY27 Growth to 30%
Acutaas Chemicals reported Q2 FY27 revenue of ₹4,369 million, up 42.7% YoY, with PAT at ₹1,231 million (up 71.4%). H1 FY27 revenue reached ₹7,665 million (up 49.3%). The company revised FY27 revenue growth guidance to ~30% and raised EBITDA margin guidance to 38-40%. The South Korea facility was inaugurated.
The significant revenue growth, improved profitability, revised positive guidance for the full fiscal year, and strategic expansion into the semiconductor ecosystem are material positive developments for the company.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for Q2 FY27 and H1 FY27. The upward revision of future guidance and the inauguration of a new manufacturing facility further contribute to a positive sentiment.
Acutaas Chemicals Limited (formerly Ami Organics Limited) announced its financial results for the second quarter and half year ended September 30, 2026, alongside an investor presentation.
For the second quarter of FY27, the company reported a robust revenue of ₹4,369 million, marking a significant year-on-year growth of 42.7%. This performance was primarily driven by the Pharmaceutical Intermediates business, although the Specialty Chemicals segment experienced a softer performance. EBITDA for the quarter grew by 84.6% to ₹1,760 million, and Profit After Tax (PAT) increased by 71.4% to ₹1,231 million. The company highlighted the inauguration of its South Korea manufacturing facility ahead of schedule, which is equipped for high-purity chemicals for semiconductor applications.
In the first half of FY27, Acutaas Chemicals achieved a revenue of ₹7,665 million, an increase of 49.3% compared to the same period last year. EBITDA for H1 FY27 stood at ₹2,890 million, up 97.7% YoY, and PAT was ₹1,981 million, a 71.0% increase YoY.
Management commentary indicated confidence in future growth, leading to a revision of the FY27 revenue growth guidance upward from 25% to around 30%. The company also raised its EBITDA margin guidance to the 38-40% range. The South Korea facility's strategic importance in capitalizing on the semiconductor ecosystem was emphasized.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.